Clinicopathological Analysis of B Cell Lymphomas, Unclassifiable; with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma in a Tertiary Care Hospital in Southern India
Abstract:(2008) to overcome the problems of difficulty in classifying certain lymphomas having overlapping morphological, immunophenotypical and genetic features. To study the clinicopathological profile of BCLu-DLBCL/BL. Crosssectional study over 3 year period in the Haematology section of Department of Pathology in a large teaching hospital in Southern India from January 2011 to December 2013. All the cases reported as BCLu-DLBCL/BL were collected and the clinical, morphological and immunohistochemical parameters we… Show more
“…However, several studies have reported that GZL may also present at extramediastinal sites. [ 2 , 6 – 8 ] Owing to the relative rarity of these lymphomas, a consensus on the appropriate therapeutic approach is yet to be achieved. Current treatment approach is based on doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), while that for CHL and DLBCL requires addition of rituximab, based on CD20 expression of the neoplastic cells.…”
Rationale:We report our experience with 2 patients diagnosed with grey zone lymphoma (GZL). The histopathological characteristics of lymphomatous tissues in these patients ranged between those of diffuse large B-cell lymphoma (DLBCL) and the classical Hodgkin lymphoma.Patient concerns:A 52-year-old female presented to the hospital with a history of lower abdominal pain of metastatic origin for 2 days. She was diagnosed with acute appendicitis and had undergone emergency surgery. A 17-year-old male was admitted to the hospital because of acute left upper abdomen pain.Diagnoses:Both patients are diagnosed of GZL primarily based on histopathology.Interventions:Both patients were treated with R-CODOX-M/R-IVAC regimen for 4 to 6 cycles.Outcomes:The short-term curative effect was complete response; no recurrence was observed as of 32-month follow-up.Lessons:R-CODOX-M/IVAC regimen exhibited relatively good curative effect. International Prognostic Index score and lactate dehydrogenase level may correlate with prognosis of these patients.
“…However, several studies have reported that GZL may also present at extramediastinal sites. [ 2 , 6 – 8 ] Owing to the relative rarity of these lymphomas, a consensus on the appropriate therapeutic approach is yet to be achieved. Current treatment approach is based on doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), while that for CHL and DLBCL requires addition of rituximab, based on CD20 expression of the neoplastic cells.…”
Rationale:We report our experience with 2 patients diagnosed with grey zone lymphoma (GZL). The histopathological characteristics of lymphomatous tissues in these patients ranged between those of diffuse large B-cell lymphoma (DLBCL) and the classical Hodgkin lymphoma.Patient concerns:A 52-year-old female presented to the hospital with a history of lower abdominal pain of metastatic origin for 2 days. She was diagnosed with acute appendicitis and had undergone emergency surgery. A 17-year-old male was admitted to the hospital because of acute left upper abdomen pain.Diagnoses:Both patients are diagnosed of GZL primarily based on histopathology.Interventions:Both patients were treated with R-CODOX-M/R-IVAC regimen for 4 to 6 cycles.Outcomes:The short-term curative effect was complete response; no recurrence was observed as of 32-month follow-up.Lessons:R-CODOX-M/IVAC regimen exhibited relatively good curative effect. International Prognostic Index score and lactate dehydrogenase level may correlate with prognosis of these patients.
In this case study, we report the rapid improvement, long-lasting complete remission, and mild toxicity of R-VNCOP-B regimen in an elderly, triple-expressor HGBL patient, with aggressive disease and poor-risk profile.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.